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Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are important causes of morbidity and mortality in South Africa (SA). The close link between CKD and the growing burden of non-communicable diseases further underscores the importance of CKD. Although renal replacement therapy in the form of dialysis is a life-saving treatment, access to dialysis in the SA public sector has remained largely unchanged since the advent of democracy. [1] The situation is worse in rural provinces such as Limpopo, where there is only one dialysis centre in the public sector. Renal failure is reported to be among the top 10 causes of natural deaths in Limpopo. [2] The cost of dialysis is a key factor preventing access to it. There is therefore a need to identify strategies to make dialysis more accessible and cost-effective.
The National Department of Health convened a summit in 2015 to discuss the challenges posed by CKD in SA and propose solutions. [3] The meeting recommended a call to increase the dialysis rate from 164 to 250 per million population (pmp) by 2025. [3] The use of private-public partnerships (PPPs) was among the strategies proposed to achieve the target figure. National Treasury defines a PPP as an agreement between the public and private sectors where the private sector is contracted to perform an institutional function on behalf of the public sector in return for a benefit. [4] The Pietersburg Hospital dialysis unit in the city of Polokwane is the first and only renal dialysis unit in the public health sector in Limpopo, and the only PPP renal unit in SA. It is important to explore the cost implications of using the PPP approach for the provision of renal dialysis services.
Few detailed costing studies on renal dialysis have been conducted in sub-Saharan Africa. [5] In 2010, Abu-Aisha et al. [6] estimated the annual cost of dialysis per patient in SA to be USD12 000 and USD7 000 for peritoneal dialysis (PD) and haemodialysis (HD), respectively. [6] A survey of renal replacement in Africa, conducted using interviews with key informants in 2007, estimated the annual cost of HD and PD to be USD20 000 and USD30 000, respectively. [7] These cost estimates omitted details of the costing approach and the cost components included. More detailed cost studies will provide the full cost of dialysis and identify the cost drivers.
Objectives
To estimate the direct cost of providing PD and HD using the PPP approach at the PPP dialysis unit in Polokwane.
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and services provided by the private partner as stipulated in the PPP contractual agreement. The renal dialysis unit provides in-centre HD and chronic ambulatory PD to public sector patients from across the province. In accordance with other public sector dialysis units, strict exclusion criteria are applied when selecting patients for dialysis. [9] A retrospective cost analysis was conducted covering the period 2007 -2012 at the renal dialysis unit. The analysis was conducted from the service provider's perspective. A renal doctor and nurse were consulted in order to identify the principal resources required to provide HD and PD. The main resources identified included both variable (pharmaceuticals and material supplies) and quasifixed (personnel, equipment, utilities and buildings) items. The cost data were sourced from both the private partner's annual audited expenditure statements and the hospital's pharmacy, finance and human resources departments. All costs were calculated in South African rands (ZAR). Table 1 describes the private and public sector key cost parameters and the data sources.
Inclusion and exclusion factors
Since the cost analysis was conducted from the provider's perspective, the indirect costs (incurred 'privately' by the patients) to access the dialysis unit were not included. The study also excluded the costs associated with surgical interventions, HD patients' access creation, PD patients' abdominal catheter procedures, and hospital admissions.
Data analysis
The derived cost and patient data were captured and analysed using Excel version 2010 (Microsoft, USA). The data collected were cleaned and necessary follow-ups were made for validation in the case of errors and/or outliers before estimating total and unit costs. For all the annual cost estimates, a discount rate of 4% was applied to account for the devaluation of cost over time.
Some of the cost components were available only in aggregated totals for both dialysis modalities. These included capital cost, human resources, laboratory tests, blood transfusions, pharmaceutical items, 
HD machines Dialysis chairs Water purification system Recurrent costs
Private partner personnel The private partner provided information on the gross salaries of their employees. This included all nursing staff, two clinical technicians, sessional staff and a unit manager.
Other recurrent costs
The private partner records were used to identify other indirect recurrent costs. These covered electricity, water, cleaning services, laundry facilities, catering and administration.
HD supplies
The annual cost of HD supplies, which included dialysers, blood line set and other medical supplies, was determined from the private partner's annual audited expenditure records.
Public sector inputs
Recurrent costs Public sector personnel The hospital's human resources department provided personnel salary cost information. These included a staff nurse, a medical clerk and medical doctors. The overtime cost for the medical officers was excluded.
Pharmaceutical items
The pharmacy department provided cost data on ward stock supplied to the renal unit. The data included all oral and intravenous medication, as well as medical supplies including renal catheters and PD catheters.
Laboratory tests
The NHLS provided monthly costs of all laboratory investigations tests ordered by the renal unit.
Blood products
The SANBS provided cost data on blood transfusion and related products ordered by the renal unit.
PD supplies
The annual PD supplies costs, which included PD fluids, disinfection caps and connecting lines, were determined from hospital invoices to suppliers. The cost of the PD supplies also included transporting supplies to patients' homes.
Utilisation data
Number of patients on chronic HD and PD The renal dialysis unit provided statistics on the average annual number of patients on chronic HD and PD. Outsourcing fee Reimbursement amount The annual reimbursement amount, which is the amount the public sector pays to the private partner, was collected from annual audited hospital expenditure reports. The reimbursement amount was based on the number of HD sessions per month, which were charged at an agreed-upon rate as stipulated in the PPP agreement with annual inflation.
Outsourcing fee
The annual outsourcing fee, which represents the additional cost of the PPP approach, was calculated by subtracting the total annual cost of private partner inputs from the annual reimbursement amount. HD = haemodialysis; PD = peritoneal dialysis; NHLS = National Health Laboratory Service; SANBS = South African National Blood Service; PPP = public-private partnership.
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laundry, cleaning and catering and other recurrent costs. To estimate the total cost of treating either HD or PD patients, these aggregate costs were apportioned to each service using allocation criteria that reflect actual resource usage. The standard operating procedures and the dialysis guidelines primarily informed the allocation of shared costs to HD and PD. Overall, we made the following assumptions in disaggregating these costs:
• HD patients are mostly hospital-based and are required to dialyse for 4 hours, three times a week. They therefore require 12 visits to the renal unit per month. • PD is mostly done at home, with a single monthly visit to the renal unit. • All patients are on a 6-week acute HD programme before being assigned to a dialysis modality. • The standard procedures for HD and PD in terms of blood transfusions and routine laboratory investigations are similar for both dialysis modalities. • The requirement for intravenous medical supplies is greater for HD patients than for those on PD because of their frequent visits to the dialysis unit and the nature of the dialysis.
Unit cost estimation
A top-down approach was used to arrive at an estimated cost per patient (unit costs) for HD and PD. The total annual cost for both HD and PD was divided by the annual number of patients on chronic HD and PD, respectively, to determine unit costs for each of the 6 years. The unit costs for 2012 were converted to US dollars (USD) using the official World Bank 2012 exchange rate, which was on average 1 USD = 8.2 ZAR (in December 2012) to allow for comparison. [10] 
Sensitivity analysis
A sensitivity analysis was conducted to test the robustness of the estimates by varying the allocation percentage for PD supplies, HD supplies, pharmaceutical items and personnel, which contributed >70% to the total cost in any given year. The uncertainty was limited to personnel cost and the cost of pharmaceutical supplies, which were apportioned to PD and HD according to the key assumptions described above. The varying of the allocation percentages for personnel costs and pharmaceutical items cost by 20% did not impact significantly on the overall unit costs estimated for PD and HD. 
Ethical considerations

Results
The number of patients on dialysis increased from 77 in 2007 to 182 in 2012 ( Fig. 1 ). More than 60% of the patients were on HD. The total cost of providing PD and HD between 2007 and 2012 was ZAR174 167 572 (before discounting). The major cost drivers were personnel (24%), PD supplies (18%), HD supplies (16%), the outsourcing fee (12%) and pharmaceutical supplies (11%) ( Table 2 ). In combination, these items accounted for 81% of the total cost.
The annual cost per patient for HD fluctuated between ZAR180 213 and ZAR215 374 ( Table 3) , whereas that for PD ranged between ZAR228 414 and ZAR264 658. The HD/PD ratio was esti mated to be 0.83 in 2012.
Discussion
Given that the Pietersburg Hospital renal dialysis unit is the only public health sector dialysis unit in Limpopo, it is not surprising that the number of patients on dialysis more than doubled between 2007 and 2012. Despite the increase in the number of dialysis patients highlighted in this study, access to dialysis remains severely limited in Limpopo, with an estimated dialysis prevalence of 59 pmp in contrast to an average of 189 pmp for SA. [1] HD was the dominant mode of dialysis, with 69.2% of patients on HD in 2012. Similarly, Okpechi et al. [11] estimated a PD proportion of 28% for SA, [11] which is higher than the estimated global average of 11%. [12] With few exceptions, the PD proportion in African countries is low; the figures for Egypt, Morocco, Tunisia and Kenya were estimated to be 0.14%, 0.62%, 3.0% and 10%, respectively. [11] In less developed countries, poor social circumstances, the cost of PD solutions, lack of access to clean water and inadequate sanitation hinder the use of PD. [11] Despite the rationing of dialysis in the public sector, provision of dialysis is expensive. The total dialysis cost for ~200 patients in 2012 was almost ZAR40 million, which used 4.4% of the hospital's total budget. In developed countries, it is estimated that 2 -3% of health expenditure is spent on treatment for patients with ESRD, although they account for a small proportion of the total population. [13] Dialysis treatment demands a significant portion of scarce financial resources while benefiting only a few patients.
Measures to curb the cost of dialysis should be directed at the main cost drivers. Personnel cost, PD supplies, HD supplies, the outsourcing fee and pharmaceutical supplies were the main cost drivers in our study, accounting for 81% of the total dialysis cost. This finding concurs with previous studies in which recurrent costs as opposed to capital expenditure were reported to be the main cost driver. [14] Decision-makers should explore various strategies to reduce the cost of dialysis supplies. For instance, the re-use of dialysers, price negotiations and reducing import duty taxes for dialysis supplies have been proposed as cost-reduction strategies. [3] In terms of the personnel cost, the national renal summit proposed a reduction of the professional nurse-to-patient ratio from the current 1:4 to 1:6, coupled with an introduction of a mid-category worker (task shifting). [3] Cautious implementation of cost-cutting measures is necessary to safeguard the quality of dialysis.
In 2012, the average annual unit costs per patient on HD and PD were estimated to be ZAR212 286 (USD25 888) and ZAR255 076 (USD31 106), respectively. These figures are higher than the USD12 000 and USD7 000 for PD and HD, respectively, reported by Abu Aisha et al. [6] in 2010. El Matri in 2008 estimated the annual cost of HD and PD in SA to be USD20 000 and USD30 000, respectively. [7] Comparison between the various estimates for SA is limited by the fact that costing approaches and cost items included were not stated in the previous studies. The outsourcing fee, which represents RESEARCH the cost of the PPP approach, contributed 12% to the total cost in the present study, and may have contributed to the higher cost estimates. Given the differences in health systems, approaches to costing, management protocols, currencies and timing of studies, the comparison of raw cost data across countries is considered to be complex. [14] However, it is useful to compare costs between countries of similar economic development and location. In a systematic review, Mushi et al. [5] reported the cost of dialysis in low-and middle-income countries. Cost-analysis studies in Chile and Brazil estimated the annual cost of HD from a societal perspective to be USD24 461 and USD30 079, respectively, and that of PD to be USD24 389 and USD28 592. [5] The annual cost of HD in African countries ranged from USD16 000 in Kenya to USD24 500 in Namibia, USD27 440 in Tanzania and USD42 784 in Nigeria; the annual cost of PD was USD12 000 in Kenya, USD24 500 in Namibia and USD47 970 in Nigeria. [5] The annual cost of PD in the present study was higher than most of the estimates from other countries, with the exception of Nigeria.
Differences between the unit cost for HD and PD and patient costs for other services in the health system are worth noting. For instance, the annual unit cost for HD and PD is substantially higher than the average annual cost per patient-day equivalent at Pietersburg Hospital, which was calculated at ZAR13 684 in 2012. Similarly, the unit cost for HD and PD is significantly higher than the average annual unit cost of providing HIV treatment in a public sector institution, which was estimated at ZAR8 705.18 (USD682.2) in 2011. [15] The HD/PD cost ratio (the annual cost per HD patient divided by the annual cost per PD patient) has been proposed to compare annual cost per patient on the two types of dialysis. [14] Despite the use of locally manufactured PD fluids, the annual cost of PD per patient was greater than that of HD in any given year, with an HD/PD ratio of 0.83 in 2012. This is consistent with previous studies, in which PD was more expensive than HD in most developing countries. [16] The use of imported PD fluids is commonly cited as the main reason for the high PD cost in developing countries. [16] In contrast, we confirmed that the PD fluids used in the Pietersburg renal unit were locally produced. The additional cost of transporting PD supplies across a rural province may have contributed to the high cost of PD v. HD.
The PPP approach is proposed as one strategy to increase access to dialysis. The outsourcing fee, which represents the additional cost of providing dialysis service through the partnership, was identified as one of the cost drivers in this study. The outsourcing fee was estimated to be ZAR20.259 million over 6 years, representing 11% of the total cost. It is difficult to make a judgement on the additional cost of the PPP approach, because there is no stipulated agreement on the national benchmark or standard for the additional costs attached to the partnership approach. Furthermore, according to National Treasury, the value-for-money criterion, which states that 'the provision of institutional function by a private partner should result in net benefit in terms of cost, price, quality, quantity and risk transfer' , is recommended for evaluating the PPP approach. [4] The risks and benefits of the PPP v. the public sector approach should therefore also be measured to comprehensively evaluate the value of the partnership.
Study limitations
This study is not without limitations. The health provider's perspective, which considers the direct cost of dialysis provision, was used to estimate the cost of dialysis in this study. Because HD is conducted at the hospital facility three times a week, by excluding its indirect costs the expenditure on HD may be underestimated. The dialysis patients in this study were selected using strict criteria that prioritised younger patients with less comorbidity; the estimates of dialysis cost will therefore apply to such a population. The study was conducted more than 6 years ago, so it is possible that the situation may have changed since 2012. However, the study is still useful for health planners because it provides a baseline assessment that outlines the costing approach and the cost components included. The fact that the study was conducted in a context of a PPP further underscores its importance in the era of universal health coverage. 
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Conclusions
The provision of dialysis for patients with ESRD is a large economic burden for the health system. In this study we estimated the annual cost for HD and PD in 2012 to be ZAR212 286 (USD25 888) and ZAR255 076 (USD31 106) per patient, respectively. Despite the fact that PD is considered a less resource-intensive dialysis therapy than HD, the annual PD cost was greater than that of HD in any given year. In order to improve efficiency of dialysis, we should prioritise measures to mitigate the main cost drivers, which included personnel cost, PD supplies, HD supplies, the outsourcing fee and pharmaceutical supplies. Furthermore, it is imperative to develop a comprehensive primary healthcare-based approach to preventing CKD. The value of methodologically sound costing studies to inform policy on the prevention and management of CKD in developing countries cannot be over-emphasised.
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